Lincocin

Lincomycin

Treatment option: Viral Infection, Infection, Infection,Bacterial, Colitis, Colitis,Pseudomembranous, Prevent Infections, Sepsis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lincocin

Quick Facts

Property	Description
Active Ingredient	Lincomycin hydrochloride monohydrate
Form	Capsule, Syrup, Solution for Injection
Pharmacological Class	Lincosamide Antibiotic
Common Use	Treatment of serious bacterial infections
Origin	Natural Fermentation Product (Streptomyces lincolnensis)

Defining the Drug and Its Origin

Lincocin is a brand name for the prescription-only antibacterial medication containing the active compound Lincomycin. This medicine is classified as an antibiotic and is designed to manage specific serious infections caused by susceptible bacterial strains. Unlike most synthetic antibiotics, Lincomycin is a natural fermentation product derived from the soil bacterium Streptomyces lincolnensis, a distinguishing feature that highlights its microbial origin. It is formulated as a single-ingredient drug, with the active substance prepared as Lincomycin hydrochloride monohydrate.

What Pharmacological Class Does Lincomycin Belong To?

Lincomycin is the foundational molecule of the lincosamide antibiotic class of antimicrobials, a category clinically recognized for its efficacy against Gram-positive bacteria. This classification is vital in clinical context because lincosamides have a distinct chemical structure and mechanism compared to common agents like penicillin. For this reason, its use is typically reserved for penicillin-allergic patients or other specific patient groups for whom penicillin is deemed inappropriate. This positions Lincocin as an established therapeutic alternative, providing reliable control over the spread of infection.

Available Forms for Lincocin

To ensure flexible administration based on patient needs and the severity of the infection, Lincocin is available in multiple high-level dosage forms. These include capsules and syrup for oral intake, as well as a sterile solution for injection intended for intramuscular or intravenous delivery. The availability of both oral and parenteral options allows healthcare providers to quickly initiate high-concentration therapy via injection before transitioning the patient to an oral form for subsequent management.

What side effects are possible with Lincocin?

Possible Side Effects and Safety Information

Lincocin's (Lincomycin) official safety profile highlights the potential for severe gastrointestinal reactions, which, in some regulatory documents, is the subject of a Boxed Warning. The most serious risk is that of Pseudomembranous Colitis or Clostridium difficile-associated diarrhea (CDAD), which can occur even up to two months after treatment is discontinued.

Adverse reactions are classified by body system and frequency. The most common reactions primarily involve the gastrointestinal tract, including diarrhea, nausea, and vomiting. Other effects are formally grouped into categories such as Skin and Subcutaneous Tissue Disorders (e.g., rash, urticaria) and Blood and Lymphatic System Disorders.

Serious Documented Adverse Reactions

The medicine is associated with rare but clinically significant reactions across multiple systems, including severe Anaphylactic Reactions (hypersensitivity), Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, and hematopoietic suppression (e.g., aplastic anemia). Serious events like cardio-respiratory arrest have been reported, specifically linked to the rapid rate of intravenous administration.

Safety Considerations for Specific Populations

Official labeling contains specific notes for certain groups. Caution is advised for older adults, who may tolerate gastrointestinal effects less well. Patients with severe hepatic or renal impairment may experience a prolonged half-life of the drug. For neonates and premature infants, the injectable form contains a preservative that has been associated with specific, serious safety concerns.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose scope

Category	Official Regulatory Statement
Documented overdose presentations	Overdose primarily leads to the increased frequency and/or severity of documented adverse effects, especially severe gastrointestinal symptoms such as diarrhea, nausea, and vomiting.
Physiological systems affected (as stated in label)	Gastrointestinal system (severe diarrhea, fluid/electrolyte imbalance), Cardiovascular system (risk of cardio-respiratory arrest), and Integumentary system (severe hypersensitivity reactions and SCAR) [Source 1.4, 2.4].
Dose-related or exposure-related factors	The risk of cardio-respiratory arrest is specifically associated with rapid intravenous administration at concentrations or rates exceeding official recommendations [Source 1.4, 2.3].
Population-specific overdose notes	Severe renal or hepatic impairment prolongs the drug's half-life, increasing exposure risk and necessitating caution [Source 2.1, 2.5]. The benzyl alcohol preservative in the injectable solution is associated with the potentially fatal "Gasping Syndrome" in neonates [Source 1.4, 2.4].
Emergency-response statements	Individuals should seek immediate medical attention for any suspected overdose [Source 2.2]. For severe hypersensitivity reactions (e.g., anaphylaxis), Lincocin must be discontinued and immediate emergency treatment with epinephrine and oxygen initiated [Source 1.4, 2.4].
When immediate medical help is required	Urgent help is required for any suspected overdose and for the manifestation of severe, life-threatening reactions such as fatal colitis or cardio-respiratory symptoms [Source 1.4, 2.2, 2.4].

Overdose Classifications (High-Level)

Classification	Official Regulatory Statement
Severity classification (as defined in official documents)	Overdose may be associated with life-threatening complications, including fatal colitis and severe systemic events [Source 1.4, 2.4].
Overdose-context constraints	No specific antidote is known; management is limited to symptomatic and supportive measures [Source 1.2, 4.2].

Resulting Overdose Structure

Official overdose statements:

No specific antidote is known for Lincomycin overdose; management is limited to symptomatic and supportive measures as the primary intervention [Source 1.2, 4.2].
Overdose can result in an exacerbation of known adverse effects, including severe gastrointestinal symptoms and an increased risk of severe hypersensitivity reactions [Source 1.2].
Regulatory documents highlight the risk of life-threatening outcomes, including fatal colitis associated with C. difficile and cardio-respiratory arrest related to overly rapid intravenous administration [Source 1.4, 2.4].
Immediate emergency action is mandated: individuals are instructed to seek immediate medical attention for any suspected overdose [Source 2.2].
Patients with severe renal or hepatic impairment may require serum level monitoring due to prolonged clearance times, which heighten the risk of severe drug exposure [Source 2.1, 2.5].

Connection to the overall overdose profile

The regulatory profile defines Lincomycin overdose as a scenario that escalates the drug’s inherent risks, particularly the potential for severe gastrointestinal toxicity and acute systemic life-threatening events. Since no specific antidote is known, regulatory guidance mandates seeking immediate medical attention to initiate necessary hospital-level symptomatic care and to monitor for highly vulnerable populations or severe complications.

Therapeutic Uses of Lincocin

What Lincocin Treats: Main Uses and Benefits

Lincocin (Lincomycin) is an antibiotic generally reserved for managing serious bacterial infections caused by susceptible organisms, such as staphylococci and streptococci.

Lincocin is commonly used across conditions presenting with acute episodes and symptoms that create noticeable physiological strain caused by deep-seated bacterial invasion. This includes addressing infections of the bone (osteomyelitis), joints (septic arthritis), and severe soft tissues. Applied in clinical settings that involve acute or unstable symptom patterns, it plays a role in managing the bacterial cause, contributing to the easing of severe localized symptoms like inflammation, pain, and swelling, and supports general well-being during symptomatic phases.

The medication is relevant for easing symptoms that interfere with daily comfort, such as high fever and generalized malaise associated with serious systemic infections. It is applied when supportive symptom management is appropriate, relevant for penicillin-allergic patients or other patients for whom a penicillin is considered relevant when first-line options are inappropriate.

Quick Fact: Symptomatic Support for Serious Infections
Primary Focus	Deep-seated and systemic bacterial infections.
Symptom Domains	Localized inflammation (swelling, pain), systemic distress (fever).
Contextual Use	As a therapeutic alternative for penicillin-allergic patients.
Patient Benefit	Supports general well-being and helps patients cope more steadily with difficult episodes.

Regulatory References

NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility for Lincocin Use: Official Regulatory Status

Official prescribing information defines who is eligible for Lincocin (Lincomycin) use by setting clear population-based restrictions, contraindications, and cautionary guidelines.

Eligibility Status	Population Rule
Contraindicated (Must Not Use)	Patients with a history of hypersensitivity to lincomycin or clindamycin. Preparations containing benzyl alcohol are contraindicated for newborns and infants due to associated risks.
Not Established	Safety and efficacy are not established for infants younger than 1 month of age (neonates).
Not Recommended	The medicine should not be used for nonbacterial infections (e.g., most upper respiratory tract infections).

Eligibility is conditional for several patient groups. Individuals with severe renal impairment or abnormal hepatic function require special caution due to potential drug clearance issues. Caution is also mandated for patients with a history of gastrointestinal disease, particularly colitis, and for older adults due to increased monitoring needs.

For pregnant women, use is permitted only if clearly needed and the expected benefits outweigh potential fetal risks. Nursing mothers must be advised to discontinue either the drug or breastfeeding, as the medicine is excreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lincocin (Lincomycin) through mandatory restrictions, pharmacokinetic considerations, and specific pharmacodynamic effects.

Documented Pharmacodynamic Interactions and Restrictions

Neuromuscular Blocking Agents: Lincocin may enhance the action of these medicines, such as rocuronium or succinylcholine, potentially prolonging neuromuscular blockade due to the drug's inherent properties.
Erythromycin: Co-administration with Erythromycin is restricted due to demonstrated pharmacodynamic antagonism; these medicines should not be used concurrently.
Live Bacterial Products: The drug's antibacterial activity results in pharmacodynamic antagonism with live bacterial vaccines (e.g., Cholera Vaccine) and microbiota oral products. This necessitates a mandatory separation of administration timing by up to two weeks for vaccines and several days for microbiota products.

Pharmacokinetic and Substance-Specific Interactions

Clearance Modification: In patients with severe renal impairment or abnormal hepatic function, the serum half-life of Lincomycin may be prolonged (reduced clearance) due to altered elimination.
Oral Contraceptives: Lincomycin may potentially decrease the effectiveness of estrogen-containing oral contraceptives through the disruption of normal gastrointestinal flora.
Ascorbic Acid (Vitamin C): The therapeutic efficacy of Lincomycin can be decreased when co-administered with Ascorbic Acid.
Physical Incompatibilities: The sterile solution for injection is physically incompatible with solutions containing Novobiocin or Kanamycin.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Assembly

The core mechanism of Lincomycin involves binding directly to the 23S ribosomal RNA of the bacterial 50S ribosomal subunit. This interaction physically blocks the ribosomal machinery, specifically interfering with the translocation required to build new protein chains. The resulting physiological effect is the complete arrest of microbial proliferation, leading to a bacteriostatic state where the pathogen population can no longer multiply.

Biological Constraints on Mechanism Functional Capacity

The functional capacity of Lincomycin’s mechanism is physiologically defined by the ability of the molecule to reach and bind its target. This functional capacity is naturally constrained by the physical barrier of the Gram-negative outer membrane, which prevents sufficient drug entry. Furthermore, the mechanism can be overridden by acquired bacterial defenses, such as efflux pumps actively expelling the drug or molecular modification of the ribosomal target site itself, leading to reduced drug affinity.

Dosage and Administration Information

How Lincocin is Used: Official Administration Guidelines

Lincocin (Lincomycin) is administered through several official routes, depending on the patient's clinical context and the severity of the infection. The approved routes include oral (using capsules or syrup), intramuscular (IM) injection, and intravenous (IV) infusion.

Dosing and Frequency

The dosage schedule is directly proportional to the severity of the infection. For serious adult infections, the oral dose is typically 500 mg every 8 hours. For more severe infections, the dose may be increased, or the frequency adjusted. The IM injection is typically 600 mg every 24 hours. Intravenous administration generally involves 600 mg to 1 gram infused every 8 to 12 hours, with maximum daily doses reaching up to 8 grams in life-threatening situations.

Administration Conditions

Oral administration requires specific timing to maximize absorption: patients are advised to take the medicine with water and to avoid taking anything by mouth (other than water) for 1 to 2 hours before and after the dose. Parenteral administration has strict procedural requirements: the sterile solution for injection must be diluted (e.g., 1 gram in 100 mL solution) and administered as an infusion over a minimum of 60 minutes. It must never be injected undiluted as a bolus, and the infusion rate must not exceed 1 gram per hour.

Population-Specific Rules

Official labels detail dose modifications for specific groups. For adults with severe renal impairment, the dose is typically reduced to 25% to 30% of the usual dose. In pediatric patients older than one month, dosing is weight-based. When treating infections caused by beta-hemolytic streptococci, the course of Lincocin should be continued for at least 10 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lincocin (Lincomycin)

Evidence for Use in Deep-Seated Serious Bacterial Infections

Research exploring Lincomycin has focused heavily on its use in research settings for deep-seated serious bacterial infections, such as those affecting the bones, joints, and severe soft tissues. As an antibiotic reserved for specific patient groups, the research was studied where alternative treatments, like penicillin, were considered inappropriate. The foundational evidence for Lincocin was collected through non-comparative clinical studies and older open-label, interventional studies.

These studies examined clinical endpoints such as patient-reported discomfort and changes in fever, alongside microbiological outcomes to track the status of bacterial strains. Findings describe patterns observed over defined time intervals, particularly concerning how outcomes related to physical discomfort evolved in the observed populations.

Study Designs and Outcomes Examined

The research base includes a mixture of older comparative trials and retrospective analyses. While Lincomycin was evaluated in these settings, the evidence quality varies across studies, with many designs being open-label or involving modest sample sizes. The research provides insight into short-term changes observed under specific conditions, rather than definitive, large-scale comparisons.

Evidence in Specific Patient Groups

Research examined Lincomycin primarily in adults with clinically serious infections. Due to its classification, a key focus involves populations that included patients with a known penicillin allergy. Research monitored these groups, helping to show what has been observed so far in this specific context.

What Is Still Uncertain About Lincocin’s Research Base

The certainty remains low regarding the current research base when compared to modern regulatory standards. A key limitation is the lack of modern, adequate, and well-controlled comparative evidence (Randomized Controlled Trials or RCTs) against newer antibiotics. The evidence quality varies, as much of the existing data is historical. The research highlights that Lincomycin was studied for serious bacterial conditions, but comparative outcomes and long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Lincocin (FAQ)

Q: Can Lincocin cause diarrhea or stomach upset?

A: Official documentation lists gastrointestinal effects, including diarrhea, nausea, and vomiting, among the most common adverse reactions observed. This is attributed to the antibiotic's known effect of altering the normal balance of bacteria in the gut. The most serious risk is that of colitis, which is why official warnings emphasize this possibility.

Q: Does Lincocin interact with birth control pills?

A: The official product information indicates that Lincomycin may potentially decrease the effectiveness of estrogen-containing oral contraceptives (birth control pills). This possible effect is believed to occur through the disruption of the normal bacteria found in the gastrointestinal flora.

Q: Are there any common foods or drinks to avoid while using Lincocin?

A: The official administration instructions state that for the oral form of the medicine, nothing should be taken by mouth (other than water) for one to two hours before and after the dose. This condition is specified to support the proper absorption of the medicine.

Q: Is Lincocin use affected by having liver problems?

A: Official warnings state that caution is advised for patients who have severe hepatic impairment, meaning reduced liver function. In this population, the clearance (elimination) of Lincomycin may be prolonged, which is a factor considered when establishing the appropriate dose.

Q: Can someone with kidney issues use Lincocin?

A: Official regulatory labels indicate that patients with kidney issues can use Lincocin, but its use involves specific considerations. For instance, those with severe renal impairment (poor kidney function) typically require a dose modification, which is often a reduction to 25% to 30% of the usual dose.

Q: Are there specific age restrictions for using Lincocin?

A: Yes, there are age restrictions defined in the official product information. The safety and efficacy of Lincocin are not established for infants who are younger than one month of age. Dosing instructions are defined for pediatric patients who are older than one month.

Q: What are the signs of a serious problem with the kidneys while on Lincocin?

A: Regulatory documents list serious adverse reactions related to the kidneys, which can include things like oliguria (reduced urine output) and renal impairment. Patients with pre-existing kidney conditions are advised to use the drug with caution. Official patient information often describes that any concerning or worsening side effects should be brought to the attention of a healthcare provider.

Q: Is Lincocin still widely used today?

A: Official documentation indicates that Lincocin is generally reserved for use in treating serious infections where less toxic antibiotics are considered inappropriate, or for specific patient groups, such as those with a known penicillin allergy. This suggests its use is targeted rather than widespread.

Q: Is Lincocin used to treat infections outside of the hospital?

A: Lincocin is officially available in both intravenous/intramuscular injection forms, which are often administered in hospital settings, and oral forms (capsules and syrup). The oral forms allow for the potential management of infections outside of the hospital setting.

Q: Does Lincocin help with skin infections?

A: Official indications for Lincomycin include the treatment of serious infections of the skin and soft-tissue structures. This use is limited to infections caused by specific susceptible bacteria, such as strains of staphylococci and streptococci.

Q: What types of bacteria is Lincocin effective against?

A: Lincomycin is active against many Gram-positive aerobic microorganisms, which include bacteria like Staphylococcus aureus, streptococci, and pneumococci. It is also effective against many anaerobic bacteria, which can cause deep-seated infections.

Q: What is the difference between Lincocin and Clindamycin?

A: Lincomycin is the original compound in the lincosamide class of antibiotics. Clindamycin is a semisynthetic derivative of lincomycin that is also classified within the lincosamide class. They share a similar foundational structure and mechanism of action.

Q: Can I take Lincocin if I am also taking a muscle relaxer?

A: Official regulatory documents describe that Lincomycin may enhance the action of neuromuscular blocking agents. Since some muscle relaxers fall into this category, this co-administration may potentially prolong neuromuscular blockade.

Q: Does Lincocin interact with blood thinners like warfarin?

A: Like some other antibiotics, Lincomycin is documented in some authoritative sources as potentially enhancing the effect of anticoagulants, which are commonly known as blood thinners like warfarin. This interaction is associated with a potential increase in the risk of bleeding.

Q: What happens if a dose of Lincocin is missed?

A: Patient instructions typically state that if a dose is missed, the patient should proceed with the next scheduled dose when it is due. Official guidance often indicates that a double dose should not be taken to compensate for a missed dose.

Q: Is Lincocin considered a 'broad-spectrum' antibiotic?

A: No, Lincocin is not considered a true broad-spectrum antibiotic. It has a known spectrum of activity against Gram-positive bacteria and most anaerobes, which is considered a narrower range compared to agents that also cover many Gram-negative aerobic organisms.

Q: Why is Lincocin sometimes reserved for more serious infections?

A: Official warnings state that due to the potential for rare but sometimes severe intestinal problems, such as colitis, the medicine should only be used to treat serious infections. It is reserved for cases where less toxic antibiotics are considered inappropriate for the patient's condition.

Q: Can Lincocin be used by children?

A: Yes, the drug is officially approved for use in pediatric patients who are older than one month of age. Specific weight-based dosing schedules are defined for this age group.

Q: Are there studies about Lincocin use in older adults?

A: Official labeling contains a section dedicated to Geriatric Use, which indicates this population has been evaluated in the context of the drug’s safety profile. This section advises caution for older adults due to a potentially increased risk of gastrointestinal side effects.

Q: What should be done if a patient feels dizzy after receiving Lincocin?

A: Regulatory documents list dizziness and vertigo as potential adverse reactions associated with the medicine. Official patient information often describes that any concerning or worsening side effects should be brought to the attention of a healthcare provider.

Q: Is it possible to be allergic to Lincocin but not penicillin?

A: Yes, it is possible. Lincomycin is chemically and mechanistically distinct from penicillin. While it is often used as an alternative for penicillin-allergic patients, the official label contains a separate contraindication for individuals with known hypersensitivity to Lincomycin itself.

Q: Does Lincocin contain any ingredients that cause problems for people with specific allergies?

A: Yes, the sterile solution for injection contains a preservative called benzyl alcohol. Official warnings state that benzyl alcohol has been associated with specific, serious safety concerns in newborns and premature infants, and its use is therefore contraindicated in that population.

Q: Is Lincocin effective against MRSA (methicillin-resistant Staphylococcus aureus)?

A: The official labels state the drug is active against Staphylococcus species, which can include MRSA. However, clinical use can be complicated by bacterial resistance mechanisms, so the effectiveness depends on the specific strain causing the infection.

Q: Is Lincocin available as a pill, or just as an injection?

A: Lincocin is officially available in both forms. It comes as a sterile solution intended for injection (intravenous or intramuscular use) and in oral forms, including capsules (commonly called pills) and syrup.

Q: How does Lincocin affect the natural bacteria in the gut?

A: Like other antibiotics, Lincocin can alter the normal balance of bacteria (flora) in the intestine. Official warnings emphasize that this change may allow for the overgrowth of Clostridium difficile, a bacteria that can cause serious inflammation of the colon (colitis).

Q: Why do doctors switch some patients from Lincocin to another antibiotic?

A: Official documents define the mechanism of acquired bacterial resistance. Bacterial strains can modify their ribosomal target site or develop efflux pumps, which can lead to reduced drug affinity. This lack of effectiveness against a resistant strain would necessitate switching to a different medicine.

Q: Can Lincocin be used for treating dental infections?

A: Official indications for Lincomycin include the treatment of serious infections caused by susceptible organisms. Some authoritative sources include oro-dental (mouth and teeth) infections in the list of conditions where it may be indicated.

Q: Can Lincocin cause trouble sleeping?

A: While trouble sleeping (insomnia) is not always explicitly listed, the official documents describe adverse reactions involving the nervous system. These include reports of headache and dizziness, which are classified under nervous system disorders.

Q: What is the difference in how Lincocin is used compared to other common antibiotics?

A: Official documents state that Lincocin is typically reserved for specific types of serious infections. It is often considered for patients who cannot take more common agents, such as those with a known allergy to penicillin.

Q: Are there long-term side effects associated with Lincocin use?

A: Official warnings note that the most serious risk, Pseudomembranous Colitis (C. difficile infection), can occur up to two months or more after treatment has been discontinued. Patients should be aware of this potential delayed effect.

Q: Do studies support the use of Lincocin for serious deep-tissue infections?

A: The official research evidence section states that the drug has been examined in studies focusing on deep-seated serious bacterial infections, such as those affecting the bones, joints, and soft tissues. It was evaluated as an alternative treatment for specific patient groups.

Q: Can Lincocin affect your mood or mental state?

A: The official list of adverse reactions includes categories for psychiatric disorders. However, specific details on common mood changes or mental state are generally not prominent in the regulatory information, with reactions in this class typically being rare or of unknown frequency.

Q: Does the body develop resistance to Lincocin over time?

A: Official documents explicitly describe that the bacteria causing the infection can develop resistance mechanisms to Lincomycin over time. This happens when the bacterial strains modify their drug target, which may limit the drug's effectiveness.

How should Lincocin be stored and disposed of?

How to Store and Dispose of Lincocin?

Lincocin (lincomycin) must be stored and handled according to official regulatory labeling to ensure stability.

Storage Requirements

Requirement	Official Condition
Temperature	Store at controlled room temperature (20 C to 25 C).
Environmental	The solution must be protected from light and must not be frozen.
Child Safety	Keep out of the sight and reach of children.

Handling and Disposal

The intravenous solution, once diluted, is typically stable for 24 hours at room temperature and must be discarded afterward. Unused or expired Lincocin should be disposed of through a drug take-back program. If one is unavailable, the medicine must be mixed with an undesirable substance, sealed, and placed in the trash. Do not flush Lincocin down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.